Calcium (ca),Phosphorus( P) and 25-hydroxyvitamin D(25OHD)] in Infants Born ≤ 32 PMA Gestational Weeks (GA) (Ca-P)
Primary Purpose
Infant, Premature, Diseases
Status
Unknown status
Phase
Phase 3
Locations
Poland
Study Type
Interventional
Intervention
Cholecalciferol 400
Cholecalciferol 800
Cholecalciferol 1200
Sponsored by
About this trial
This is an interventional screening trial for Infant, Premature, Diseases focused on measuring premature, osteopenia, Vit. D, LBW (low birth weight), 25OHD
Eligibility Criteria
Inclusion Criteria:
- gestational age ≤32 weeks at birth
- hospitalization in the department no later than at the age of 7 days (for infants born outside the center)
- No birth defects or diseases permanently affecting the ability to accept enteral feeding
- Anticipated possibility of continuous monitoring of the course of treatment in hospital until discharge
- Consent of Parents / legal guardians for the participation in the study.
Exclusion criteria
- gestational age> 32 weeks at birth
- the beginning of hospitalization in the department later than the age of 7 days (for infants born outside the center)
- presence of congenital defects or diseases permanently affecting the ability to accept enteral feeding (e.g.oesophageal atresia, anal atresia, congenital umbilical hernia, gastroschisis, syndromes genetically determined)
- significant interruption (> 1 week) of the hospitalization in the center
- lack of consent of the Parents / legal guardians to participation in the study
Sites / Locations
- SPSK im. prof. W.Orłowskiego CMKP Neonatology DepartamentRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Active Comparator
Experimental
Arm Label
Lower dose
Middle dose
Higher dose
Arm Description
cholecalciferol 400UNT, oral solution
cholecalciferol 800UNT, oral solution
cholecalciferol 1200UNT, oral solution,
Outcomes
Primary Outcome Measures
Serum 25OHD levels in cord blood in Polish preterm infants
assessment of 25OH D levels in children deficiency: <10ng/ml, insufficient level: 10-30ng/ml, sufficient level: 30-50ng/ml
Secondary Outcome Measures
Impact of supplementation of Vit. D during pregnancy on 25OHD serum level in Polish mothers
assessment of 25OH D levels in mothers deficiency: <10ng/ml, insufficient level: 10-30ng/ml, sufficient level: 30-50ng/ml
Impact of dosage of Vit D3 (400/800/1200 UNT per day) on serum 25OH D levels in preterm children
assessment of serum 25OH D levels in children deficiency: <10ng/ml, insufficient level: 10-30ng/ml, sufficient level: 30-50ng/ml; high level > 60ng/ml, toxic level > 100ng/ml
Impact of dosage of Vit D3 (400/800/1200 UNT /per day) on Ca serum levels
assessment of Ca serum levels in children
Impact of dosage of Vit D3 (400/800/1200 UNT /per day) on P serum levels
assessment of P serum levels in children
Impact of dosage of Vit D3 (400/800/1200 UNT /per day) on urinary Ca excretion
assessment of urinary calcium/creatinine index
Impact of dosage of Vit D3 (400/800/1200 UNT /per day) on urinary P excretion
assessment of urinary P/creatinine index (mg/mg)
impact of total annual Vit D3 dose and bone calcification in children
assessment of bone status :Densitometry (DEXA)
correlation of cord blood 25OHD level and GA
birth <24 GA, 24-28GA, 28-32GA
impact of cord blood 25OHD level on birth weight
assessment of percentile of birth weight (Fenton 2013) hypotrophy <3p, eutrophy 3-97p, hypertrophy >97p
Full Information
NCT ID
NCT03691896
First Posted
June 18, 2016
Last Updated
September 28, 2018
Sponsor
Centre of Postgraduate Medical Education
1. Study Identification
Unique Protocol Identification Number
NCT03691896
Brief Title
Calcium (ca),Phosphorus( P) and 25-hydroxyvitamin D(25OHD)] in Infants Born ≤ 32 PMA Gestational Weeks (GA)
Acronym
Ca-P
Official Title
The Impact of the Dose of Vitamin D (vitD) on the Metabolism of ca, p and Concentrations of 25OHD, Bone Status and Development of Premature Infants up to 2 Years of Age. Prospective, Randomized, Clinical Study
Study Type
Interventional
2. Study Status
Record Verification Date
September 2018
Overall Recruitment Status
Unknown status
Study Start Date
January 2016 (undefined)
Primary Completion Date
December 2019 (Anticipated)
Study Completion Date
December 2019 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Centre of Postgraduate Medical Education
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
It has not yet been established the optimal dose of vit. D for preterm infants in Poland. It is not known what dose of vit. D will provide the correct concentration of vit. D and the optimal development of the skeleton of the premature.
The study will try to determine the optimal supplementation of vitamin D and the supply of Ca and P for normal growth and development of a child born prematurely.
In addition, the investigators will evaluate any risk factors for deficiency and excess of vitamin D and the consequences of its deficiency and overdose. Simultaneously the study would make possible the determination of an optimal schedule for controlling the Ca-P levels in the group of the youngest infants born prematurely. In addition, the study will assess the relationship between maternal and newborn vitamin D resources right after birth, and the incidence of vitamin D deficiency in infants born prematurely. Preterm infants will be randomized in 3 groups assigned to different doses of vit. D. The study will investigate the metabolism of calcium, phosphorus, the health of bones and development of the premature babies till the age of 2.
Detailed Description
The participants of the study will be prematures, born ≤32 GA, hospitalized in the Department of Neonatology, in the neonatal intensive care unit. Hospitalized patients who meet the inclusion criteria will be randomized in 3 groups assigned to different doses of vit. D (400, 800 or 1200 units(UNT) of vitamin D).
At defined age points of postnatal life, parameters of calcium and phosphorus metabolism and vitamin D level will be tested, along with the health of bones, health status and development.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Infant, Premature, Diseases
Keywords
premature, osteopenia, Vit. D, LBW (low birth weight), 25OHD
7. Study Design
Primary Purpose
Screening
Study Phase
Phase 3
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
200 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Lower dose
Arm Type
Experimental
Arm Description
cholecalciferol 400UNT, oral solution
Arm Title
Middle dose
Arm Type
Active Comparator
Arm Description
cholecalciferol 800UNT, oral solution
Arm Title
Higher dose
Arm Type
Experimental
Arm Description
cholecalciferol 1200UNT, oral solution,
Intervention Type
Dietary Supplement
Intervention Name(s)
Cholecalciferol 400
Other Intervention Name(s)
vit D
Intervention Description
dose 400 UNT/day for 12 months
Intervention Type
Dietary Supplement
Intervention Name(s)
Cholecalciferol 800
Other Intervention Name(s)
vit D
Intervention Description
dose 800 UNT/day for 12 months
Intervention Type
Drug
Intervention Name(s)
Cholecalciferol 1200
Other Intervention Name(s)
vit D
Intervention Description
dose 1200 UNT/day for 12 months
Primary Outcome Measure Information:
Title
Serum 25OHD levels in cord blood in Polish preterm infants
Description
assessment of 25OH D levels in children deficiency: <10ng/ml, insufficient level: 10-30ng/ml, sufficient level: 30-50ng/ml
Time Frame
day of labour
Secondary Outcome Measure Information:
Title
Impact of supplementation of Vit. D during pregnancy on 25OHD serum level in Polish mothers
Description
assessment of 25OH D levels in mothers deficiency: <10ng/ml, insufficient level: 10-30ng/ml, sufficient level: 30-50ng/ml
Time Frame
day of labour
Title
Impact of dosage of Vit D3 (400/800/1200 UNT per day) on serum 25OH D levels in preterm children
Description
assessment of serum 25OH D levels in children deficiency: <10ng/ml, insufficient level: 10-30ng/ml, sufficient level: 30-50ng/ml; high level > 60ng/ml, toxic level > 100ng/ml
Time Frame
4,8,12 weeks of life,1 and 2 years of age
Title
Impact of dosage of Vit D3 (400/800/1200 UNT /per day) on Ca serum levels
Description
assessment of Ca serum levels in children
Time Frame
4,8,12 weeks of life,1 and 2 years of age
Title
Impact of dosage of Vit D3 (400/800/1200 UNT /per day) on P serum levels
Description
assessment of P serum levels in children
Time Frame
4,8,12 weeks of life,1 and 2 years of age
Title
Impact of dosage of Vit D3 (400/800/1200 UNT /per day) on urinary Ca excretion
Description
assessment of urinary calcium/creatinine index
Time Frame
4,8,12 weeks of life,1 and 2 years of age
Title
Impact of dosage of Vit D3 (400/800/1200 UNT /per day) on urinary P excretion
Description
assessment of urinary P/creatinine index (mg/mg)
Time Frame
4,8,12 weeks of life,1 and 2 years of age
Title
impact of total annual Vit D3 dose and bone calcification in children
Description
assessment of bone status :Densitometry (DEXA)
Time Frame
average of 1 and 2 years of age
Title
correlation of cord blood 25OHD level and GA
Description
birth <24 GA, 24-28GA, 28-32GA
Time Frame
1st day of life
Title
impact of cord blood 25OHD level on birth weight
Description
assessment of percentile of birth weight (Fenton 2013) hypotrophy <3p, eutrophy 3-97p, hypertrophy >97p
Time Frame
1st day of life of age
10. Eligibility
Sex
All
Minimum Age & Unit of Time
24 Weeks
Maximum Age & Unit of Time
32 Weeks
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
gestational age ≤32 weeks at birth
hospitalization in the department no later than at the age of 7 days (for infants born outside the center)
No birth defects or diseases permanently affecting the ability to accept enteral feeding
Anticipated possibility of continuous monitoring of the course of treatment in hospital until discharge
Consent of Parents / legal guardians for the participation in the study.
Exclusion criteria
gestational age> 32 weeks at birth
the beginning of hospitalization in the department later than the age of 7 days (for infants born outside the center)
presence of congenital defects or diseases permanently affecting the ability to accept enteral feeding (e.g.oesophageal atresia, anal atresia, congenital umbilical hernia, gastroschisis, syndromes genetically determined)
significant interruption (> 1 week) of the hospitalization in the center
lack of consent of the Parents / legal guardians to participation in the study
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Magdalena Zarlenga, MD
Phone
+48224851171
Email
magda.cmkp@gmail.com
First Name & Middle Initial & Last Name or Official Title & Degree
Maria Wilińska, DSc
Phone
+48225841170
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Magdalena Zarlenga, MD
Organizational Affiliation
Mc postgraduate SPSK im prof.W.Orłowskiego Warszawa
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Maria Wilińska, DSc
Organizational Affiliation
Mc postgraduate SPSK im prof.W.Orłowskiego Warszawa
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Ewa Głuszczak-Idziakowska, PhD
Organizational Affiliation
Mc postgraduate SPSK im prof.W.Orłowskiego Warszawa
Official's Role
Principal Investigator
Facility Information:
Facility Name
SPSK im. prof. W.Orłowskiego CMKP Neonatology Departament
City
Warszawa
State/Province
Mazowieckie
ZIP/Postal Code
00-416
Country
Poland
Individual Site Status
Recruiting
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
24124195
Citation
Bodnar LM, Klebanoff MA, Gernand AD, Platt RW, Parks WT, Catov JM, Simhan HN. Maternal vitamin D status and spontaneous preterm birth by placental histology in the US Collaborative Perinatal Project. Am J Epidemiol. 2014 Jan 15;179(2):168-76. doi: 10.1093/aje/kwt237. Epub 2013 Oct 11.
Results Reference
background
PubMed Identifier
23852093
Citation
Monangi N, Slaughter JL, Dawodu A, Smith C, Akinbi HT. Vitamin D status of early preterm infants and the effects of vitamin D intake during hospital stay. Arch Dis Child Fetal Neonatal Ed. 2014 Mar;99(2):F166-8. doi: 10.1136/archdischild-2013-303999. Epub 2013 Jul 13.
Results Reference
background
PubMed Identifier
24515510
Citation
Natarajan CK, Sankar MJ, Agarwal R, Pratap OT, Jain V, Gupta N, Gupta AK, Deorari AK, Paul VK, Sreenivas V. Trial of daily vitamin D supplementation in preterm infants. Pediatrics. 2014 Mar;133(3):e628-34. doi: 10.1542/peds.2012-3395. Epub 2014 Feb 10.
Results Reference
background
PubMed Identifier
23902955
Citation
van de Lagemaat M, Rotteveel J, Schaafsma A, van Weissenbruch MM, Lafeber HN. Higher vitamin D intake in preterm infants fed an isocaloric, protein- and mineral-enriched postdischarge formula is associated with increased bone accretion. J Nutr. 2013 Sep;143(9):1439-44. doi: 10.3945/jn.113.178111. Epub 2013 Jul 31.
Results Reference
background
PubMed Identifier
1635820
Citation
Schanler RJ, Burns PA, Abrams SA, Garza C. Bone mineralization outcomes in human milk-fed preterm infants. Pediatr Res. 1992 Jun;31(6):583-6. doi: 10.1203/00006450-199206000-00009.
Results Reference
background
PubMed Identifier
18353060
Citation
Kislal FM, Dilmen U. Effect of different doses of vitamin D on osteocalcin and deoxypyridinoline in preterm infants. Pediatr Int. 2008 Apr;50(2):204-7. doi: 10.1111/j.1442-200X.2008.02553.x.
Results Reference
background
PubMed Identifier
24253367
Citation
Christmann V, de Grauw AM, Visser R, Matthijsse RP, van Goudoever JB, van Heijst AF. Early postnatal calcium and phosphorus metabolism in preterm infants. J Pediatr Gastroenterol Nutr. 2014 Apr;58(4):398-403. doi: 10.1097/MPG.0000000000000251.
Results Reference
background
PubMed Identifier
10554126
Citation
Backstrom MC, Maki R, Kuusela AL, Sievanen H, Koivisto AM, Koskinen M, Ikonen RS, Maki M. The long-term effect of early mineral, vitamin D, and breast milk intake on bone mineral status in 9- to 11-year-old children born prematurely. J Pediatr Gastroenterol Nutr. 1999 Nov;29(5):575-82. doi: 10.1097/00005176-199911000-00019.
Results Reference
background
PubMed Identifier
10320530
Citation
Fewtrell MS, Prentice A, Jones SC, Bishop NJ, Stirling D, Buffenstein R, Lunt M, Cole TJ, Lucas A. Bone mineralization and turnover in preterm infants at 8-12 years of age: the effect of early diet. J Bone Miner Res. 1999 May;14(5):810-20. doi: 10.1359/jbmr.1999.14.5.810.
Results Reference
background
PubMed Identifier
23182428
Citation
McCarthy RA, McKenna MJ, Oyefeso O, Uduma O, Murray BF, Brady JJ, Kilbane MT, Murphy JF, Twomey A, O' Donnell CP, Murphy NP, Molloy EJ. Vitamin D nutritional status in preterm infants and response to supplementation. Br J Nutr. 2013 Jul 14;110(1):156-63. doi: 10.1017/S0007114512004722. Epub 2012 Nov 27.
Results Reference
background
Learn more about this trial
Calcium (ca),Phosphorus( P) and 25-hydroxyvitamin D(25OHD)] in Infants Born ≤ 32 PMA Gestational Weeks (GA)
We'll reach out to this number within 24 hrs